Contraception is a method to prevent pregnancy deliberately and any device used for this objective is referred to as contraceptive device. In addition to its primary role in averting unintended pregnancies, the contraception device also helps in protecting against sexually transmitted diseases (STDs) during intercourse. Contraceptive devices are of two types i.e., barrier contraceptive devices and hormonal contraceptive devices.

Barrier contraceptive methods operate by physically obstructing sperm from reaching a woman's uterus. This category encompasses a range of devices such as condoms, diaphragms, cervical caps, contraceptive sponges, contraceptive gels, as well as spermicides like foams, creams, and suppositories. On the other hand, hormonal contraceptive methods incorporate a combination of estrogen and progestin or solely progestin. These approaches primarily prevent pregnancy by inhibiting ovulation (the release of eggs from the ovaries) or by thickening cervical mucus to impede the passage of sperm through the cervix into the uterus. This classification encompasses options like implants, intrauterine devices (IUDs), vaginal rings, injections, and skin patches.

Contraceptive methods have experienced increased popularity over time due to their reliable ability to prevent unintended pregnancies through consistent and proper usage. Moreover, empowerment, health benefits, STDs prevention, education and awareness, gender equity, economic considerations are other factors contributing to the growing popularity and acceptance of contraceptive methods across different societies and cultures, thus helping people to exercise their right to plan their families and lead healthier lives.

The Global Contraceptive Devices Market was valued at US $16.56BN in 2022 and is expected to reach US $26.52BN by 2030, growing at a CAGR of 6.06% during the forecast period 2023 – 2030.

COVID-19 Impact on Contraceptive Devices

The coronavirus outbreak triggered fear among people leading to a consumer behavior shift. Buyers were stockpiling essentials as the infectious virus spread around the world. With recreational places such as gyms, park and theatres under a lockdown, and with many corporates allowing working from home, people started to stock up on food and hygiene products.

Interestingly, an unexpected trend was noticed with respect to condom sales, defying conventional expectations. Traditionally, a spike in demand occurs during festive period especially new year. Smaller condom packs tend to be favored over larger ones, and male condoms usually dominate the market. However, the onset of the COVID-19 crisis wrought a reversal in these patterns. Condom sales surged dramatically, with retailers in developing countries like India witnessing a remarkable uptick of approximately 25% to 50% within a single week. The unusual twist saw people purchasing larger condom packs, treating them akin to essential medicines. Additionally, there was an unexpected rise in the number of females purchasing condoms, surpassing the proportion of male buyers. Housewives were even among those requesting condoms, challenging the previously established demographics. Lockdowns, travel restrictions, and disruptions to manufacturing and transportation have, at times, affected the availability of medical supplies, including contraceptive devices. This potentially led to temporary shortages or delays in obtaining devices.

On the other hand, the demand for contraceptive devices such as implants and IUDs, which requires healthcare providers intervention decline drastically. It is because the healthcare systems faced strain due to the focus on treating COVID-19 patients. This shift in priorities might have impacted routine healthcare services, including family planning and reproductive health services leading to a sharp decline in the dispensing of these devices.

Factors Driving the Contraceptive Devices Market

Contraceptive Devices Market Drivers

Rising Rate of Unintended Pregnancies

Unintended pregnancies occur when individuals or couples conceive without prior intention or readiness to become parents at that particular time. One of the reasons for the rising rate of unintended pregnancies is failure to use contraceptive methods to avoid unintended pregnancy due to insufficient awareness, limited access, or financial constraints.

According to the latest available data from June 2023 by WHO, as of 2019, adolescents between the ages of 15 to 19 years in low- and middle-income countries (LMICs) encountered an approximate 21 million pregnancies annually, with nearly half of these pregnancies, approximately 50%, being unintended. This led to an estimated 12 million births. Moreover, analyzing data from 2019, it was observed that 55% of unintended pregnancies among adolescent girls aged 15 to 19 culminated in abortions. Regrettably, these abortion procedures are often conducted under unsafe conditions in LMICs. This data underscores the pressing need for comprehensive reproductive health and family planning initiatives to address these critical challenges. Adolescent mothers, aged 10 to 19 years, encounter elevated vulnerabilities such as eclampsia, puerperal endometritis, and systemic infections compared to women aged 20 to 24 years. Furthermore, infants born to adolescent mothers confront heightened risks like low birth weight, preterm birth, and severe neonatal conditions, emphasizing the intricate health challenges intertwined with early motherhood.

The substantial ramifications of unintended pregnancies encompass emotional strain, financial burdens, and health-related complexities, underscoring the urgency to mitigate their occurrence. This urgency has propelled a heightened focus on potent contraceptive solutions, including devices like condoms and IUDs. As a result, the contraceptive devices market is poised for promising growth in the foreseeable future, driven by the collective endeavor to alleviate these challenges and enhance individual and familial well-being. 

Contraceptive Devices Market Challenges

Side Effects and Risks Related to Contraceptive Devices

Contraceptive devices, despite their efficacy in preventing unintended pregnancies, can bring about a spectrum of side effects. Hormonal variants like patches and hormonal IUDs might trigger common discomforts such as nausea, headaches, breast tenderness, and mood fluctuations. These effects are typically transitory and ameliorate as the body acclimatizes to hormonal changes. In contrast, non-hormonal options like copper IUDs could lead to intensified menstrual bleeding and heightened cramps. It's imperative to recognize that individual responses diverge, and not everyone encounters these reactions. Furthermore, prolonged use of hormonal methods may have a temporary impact on fertility after discontinuation. Intriguingly, IUDs harbor a marginal risk of being expelled from the uterus, underscoring the necessity of regular healthcare-provider check-ins to ascertain the device's positioning.

Moreover, contraceptive devices harbor specific health risks as well. Hormonal methodologies could increase the likelihood of blood clot formation, especially among individuals with a history of clotting disorders, smokers, or those with elevated blood pressure. Select hormonal contraceptives might slightly elevate the risk of breast cancer. In rare cases, IUDs might perforate the uterus during insertion, albeit this probability remains minimal, manifesting in fewer than 1% of instances. While the insertion process entails an infection risk, adherence to proper sterilization protocols minimizes this hazard. Prior to suggesting a contraceptive method, healthcare professionals must meticulously assess an individual's medical history to ensure the chosen option aligns harmoniously with their health landscape.

The demand for contraceptive devices can be influenced by concerns regarding their potential side effects and associated risks. Addressing these apprehensions through accurate education, comprehensive counselling, and transparent communication about the benefits and risks of contraceptive devices is crucial to fostering trust and increasing their adoption rates.

Contraceptive Devices Market Trends

Introduction of Innovative Products

The landscape of contraception has been undergoing transformative changes with the introduction of innovative contraceptive devices.

The condom companies are continuously innovating in the areas such as design, size and materials used for condoms, aimed at enhancing user experience and effectiveness. Now there are ultra-thin condoms available in the market that provide a more natural feel while maintaining reliable protection. Also, Novel materials, such as polyisoprene and polyurethane, offer alternatives to latex for those with allergies or sensitivities.

For example, in March 2023, Durex launched their first non-latex condoms, made of polyisoprene material which is claimed to be softer than latex rubber and provides skin on skin feeling to partners. The brand aims to elevate the depth and quality of intimate moments while ensuring protection, redefining the sensory experience of safe intimacy.

Another example is SEX BRAND, a fresh entrant in sexual wellness domain. It’s SECONDSKIN condom launched in February 2023, aims to save sex with openness, confidence and education. It is made from bio-mimetic lubricated rubber, which is 34% thinner than a common and standard condom. Beyond emulating the authentic feel of skin, the condom bears a profound commitment to environmental and societal betterment because its is a vegan, subscription condom made using a pioneering and fully-transparent sustainable source of rubber which is part of the Regenerative Rubber Initiative. Remarkably, for every million condoms sold, SEX BRAND pledges to donate a million more to Uganda, bridging a crucial 27% gap in sexual wellness supplies for vulnerable communities.

This strategic convergence of innovation, environmental consciousness, and philanthropy underpins the evolution of the sexual wellness industry towards holistic wellbeing and impact, thereby benefiting the market revenue positively.  

Contraceptive Devices Market Segmentation

Contraceptive Devices Market by Types

• The Condom segment dominated the Contraceptive Devices Market in 2022.
• The IUDs are the fastest-growing segment, growing with the CAGR of 8.15% during the forecast period.

By type, the Global Contraceptive Devices Market comprises of namely condoms, IUDs (both hormonal and copper), injectables, patches, vaginal rings, diaphragms, cervical caps, sponges, and others. Other is further divided into contraceptive gels and spermicides (foams, creams, and suppositories).  

The Condom segment dominated the Contraceptive Devices Market in 2022 with a market share of 52.36% owing to factors such as easy availability and affordability, their effectiveness, and additional benefits such as dual protection in the sense that condoms provide dual protection by acting as a barrier method for both contraception and the prevention of sexually transmitted infections (STIs).

The IUDs are the fastest-growing segment, growing with a CAGR of 8.15% during the forecast period. IUDs are among the most effective forms of contraception available. They have a very low failure rate, which contributes to their appeal to individuals seeking reliable birth control.

Contraceptive Devices Market by Distribution Channel

• The supermarkets, hypermarkets, and convenience stores segment dominated the Contraceptive Devices Market in 2022.
• The online stores segment is the fastest-growing segment, growing with the CAGR of 7.32% during the forecast period.

By distribution channel, the global Contraceptive Devices Market is divided into supermarkets, hypermarkets, and convenience stores; retail pharmacies, hospital pharmacies and drug stores; online stores; and others. The others segment is further divided into hospitals, clinics, medical institutions, family planning organizations, and nonprofits.

The supermarkets, hypermarkets, and convenience stores segment dominated the Contraceptive Devices Market in 2022. One of the factors for its high share is that these stores provide consumer privacy. Purchasing contraceptive devices from these types of stores allows for a level of privacy that might not be as easily achieved in other settings.

The online stores segment is the fastest-growing segment, growing with the CAGR of 7.32% during the forecast period. This growth can be attributed to factors such as convenience. Online stores offer the convenience of shopping from home or any location with internet access. Consumers can browse and purchase contraceptive devices such as condom, vaginal rings, and patches etc. without the need to visit a physical store. Further, buying contraceptive devices online provides a level of privacy that some consumers may prefer. They can avoid potential embarrassment or discomfort associated with purchasing these products in person, thus contributing to market revenue.

Contraceptive Devices Market by Region

• The North America region dominated the Contraceptive Devices Market in 2022.
• The APAC region is the fastest growing segment, growing with the CAGR of 7.45% during the forecast period.

By region, the Global Contraceptive Devices Market is divided into North America, Europe, APAC, and others. Others is further divided into Middle Eastern and South America.

The North America region dominated the Contraceptive Devices Market in 2022. Economic stability, higher disposable income, and availability of wide range of contraceptive options in North America contribute to increased purchasing of contraceptive devices.

The APAC region is the fastest growing segment, growing with the CAGR of 7.45% during the forecast period. As education and awareness about reproductive health and family planning continue to improve in the APAC region, more individuals and couples will be seeking reliable contraception options.

Contraceptive Devices Market Competitive Landscape

The global Contraceptive Devices market is highly fragmented. Several major pharmaceutical companies and healthcare companies compete in this space, offering a range of contraceptive options. Differentiated products, brand recognition, and marketing efforts contribute to competitive intensity. Additionally, pricing pressures, regulatory challenges, and the need for continuous innovation also drive competition among players.

Major Players

• Church & Dwight Co., Inc. (U.S.)
• Fuji Latex Co., Ltd. (Japan)
• Reckitt Benckiser Group (U.K.)
• Karex Berhad (Malaysia)
• Lelo (Sweden)
• LifeStyles Healthcare Pte Ltd. (Belgium)
• Veru, Inc. (U.S.)
• Mayer Laboratories, Inc. (U.S.)
• Okamoto Industries, Inc. (Japan)
• Cupid Limited (India)
• Caution Wear Corp. (U.S.)
• ONE Condoms (U.S.)
• Abbvie Inc. (U.S.)
• Bayer AG (Germany)
• CooperSurgical Inc. (U.S.)
• EUROGINE, S.L. (Spain)
• Mona Lisa N.V. (Belgium)
• Pregna International Limited (India)
• Prosan International B.V. (The Netherlands)
• SMB Corporation of India (India)
• Melbea Innovations (Hungary)
• Ocon Medical Ltd. (Israel),
• Viatris Inc. (U.S.)
• Agile Therapeutics, Inc. (U.S.)
• Luye Pharma Group (China)
• Johnson & Johnson (U.S.)
• Merck & Co., Inc. (U.S.)
• Novo Nordisk (Denmark)
• Pfizer, Inc. (U.S.)
• Prasco Laboratories (U.S.)
• The Cigna Group (U.S.)
• Teva Pharmaceuticals, Inc. (Israel)
• Tree of Life Pharma Ltd. (Israel)
• The Good Glamm Group (India)
• BRANDMOVER GmbH (Switzerland)

Recent Developments

• May 2023: Good Glamm group-backed Sirona India has acquired Bleü, India's first vegan condom brand, in an all-cash deal. With this acquisition, Sirona has entered the sexual wellness category. Sirona is a leading Femtech brand, known for its feminine hygiene products and its period-tracker on WhatsApp.
• March 2023: Swiss company Brandmover, launched new sustainable Feelgood Condoms, which are vegan and produced with green electricity, according to the brand, whose motto is “Not only for vegans & animal lovers: Feelgood satisfies everyone”.

Contraceptive Devices Market Scope

Table of Contents

1 INTRODUCTION OF GLOBAL CONTRACEPTIVE DEVICES MARKET

1.1 Overview of the Market

1.2 Scope of Report

1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY

3.1 Data Mining

3.2 Validation

3.3 Primary Interviews

3.4 List of Data Sources

4 GLOBAL CONTRACEPTIVE DEVICES MARKET OUTLOOK

4.1 Overview

4.2 Market Dynamics

4.2.1 Drivers

4.2.2 Restraints

4.2.3 Opportunities

4.3 Porters Five Force Model

4.3.1. Bargaining Power of Suppliers

4.3.2. Threat of New Entrants

4.3.3. Threat of Substitutes

4.3.4. Competitive Rivalry

4.3.5. Bargaining Power among Buyers

4.4 Value Chain Analysis

5 GLOBAL CONTRACEPTIVE DEVICES MARKET, BY TYPES

5.1 Overview

5.2 Condoms

5.3 IUDs

5.4 Injectables

5.5 Patches

5.6 Vaginal Rings

5.7 Diaphragms

5.8 Cervical Caps

5.9 Sponges

5.10 Others

6 GLOBAL CONTRACEPTIVE DEVICES MARKET, BY DISTRIBUTION CHANNELS

6.1 Supermarkets, Hypermarkets, and Convenience Stores

6.2 Retail Pharmacies, Hospital Pharmacies and Drug Stores

6.3 Online Stores

6.4 Others

7 GLOBAL CONTRACEPTIVE DEVICES MARKET, BY REGION

7.1 North America

7.1.1 U.S.

7.1.2 Canada

7.2 Europe

7.2.1 Germany

7.2.3 U.K.

7.2.4 France

7.2.5 Rest of Europe

7.3 Asia Pacific

7.3.1 China

7.3.2 Japan

7.3.3 India

7.3.4 South Korea

7.3.5 Singapore

7.3.6 Malaysia

7.3.7 Australia

7.3.8 Thailand

7.3.9 Indonesia

7.3.10 Philippines

7.3.11 Rest of Asia Pacific

7.4 Others

7.4.1 Saudi Arabia

7.4.2 U.A.E.

7.4.3 South Africa

7.4.4 Egypt

7.4.5 Israel

7.4.6 Rest of Middle East and Africa (MEA)

7.4.7 Brazil

7.4.8 Argentina

7.4.9 Mexico

7.4.10 Rest of South America

8 COMPANY PROFILES

8.1 Church & Dwight Co. Inc.

8.1.1. Company Overview

8.1.2. Key Executives

8.1.3. Operating Business Segments

8.1.4. Product Portfolio

8.1.5. Financial Performance (As per availability)

8.1.6 Key News

9.1 Fuji Latex Co., Ltd.

9.1.1. Company Overview

9.1.2. Key Executives

9.1.3. Operating Business Segments

9.1.4. Product Portfolio

9.1.5. Financial Performance (As per availability)

9.1.6 Key News

10.1 Reckitt Benckiser Group

10.1.1. Company Overview

10.1.2. Key Executives

10.1.3. Operating Business Segments

10.1.4. Product Portfolio

10.1.5. Financial Performance (As per availability)

10.1.6 Key News

11.1 Karex Berhad

11.1.1. Company Overview

11.1.2. Key Executives

11.1.3. Operating Business Segments

11.1.4. Product Portfolio

11.1.5. Financial Performance (As per availability)

11.1.6 Key News

12.1 Lelo

12.1.1. Company Overview

12.1.2. Key Executives

12.1.3. Operating Business Segments

12.1.4. Product Portfolio

12.1.5. Financial Performance (As per availability)

12.1.6 Key News

13.1 LifeStyles Healthcare Pte Ltd.

13.1.1. Company Overview

13.1.2. Key Executives

13.1.3. Operating Business Segments13

13.1.4. Product Portfolio

13.1.5. Financial Performance (As per availability)

13.1.6 Key News

14.1 Veru, Inc.

14.1.1. Company Overview

14.1.2. Key Executives

14.1.3. Operating Business Segments

14.1.4. Product Portfolio

14.1.5. Financial Performance (As per availability)

14.1.6 Key News

15.1 Mayer Laboratories, Inc.

15.1.1. Company Overview

15.1.2. Key Executives

15.1.3. Operating Business Segments

15.1.4. Product Portfolio

15.1.5. Financial Performance (As per availability)

15.1.6 Key News

16.1 Okamoto Industries, Inc.

16.1.1. Company Overview

16.1.2. Key Executives

16.1.3. Operating Business Segments

16.1.4. Product Portfolio

16.1.5. Financial Performance (As per availability)

16.1.6 Key News

17.1 Cupid Limited

17.1.1. Company Overview

17.1.2. Key Executives

17.1.3. Operating Business Segments

17.1.4. Product Portfolio

17.1.5. Financial Performance (As per availability)

17.1.6 Key News

18.1 Caution Wear Corp.

18.1.1. Company Overview

18.1.2. Key Executives

18.1.3. Operating Business Segments

18.1.4. Product Portfolio

18.1.5. Financial Performance (As per availability)

18.1.6 Key News

19.1 ONE Condoms

19.1.1. Company Overview

19.1.2. Key Executives

19.1.3. Operating Business Segments

19.1.4. Product Portfolio

19.1.5. Financial Performance (As per availability)

19.1.6 Key News

20.1 Abbvie Inc.

20.1.1. Company Overview

20.1.2. Key Executives

20.1.3. Operating Business Segments

20.1.4. Product Portfolio

20.1.5. Financial Performance (As per availability)

20.1.6 Key News

21.1 Bayer AG

21.1.1. Company Overview

21.1.2. Key Executives

21.1.3. Operating Business Segments

21.1.4. Product Portfolio

21.1.5. Financial Performance (As per availability)

21.1.6 Key News

22.1 CooperSurgical Inc.

22.1.1. Company Overview

22.1.2. Key Executives

22.1.3. Operating Business Segments

22.1.4. Product Portfolio

22.1.5. Financial Performance (As per availability)

22.1.6 Key News

23.1 EUROGINE, S.L.

23.1.1. Company Overview

23.1.2. Key Executives

23.1.3. Operating Business Segments

23.1.4. Product Portfolio

23.1.5. Financial Performance (As per availability)

23.1.6 Key News

24.1 Mona Lisa N.V.

24.1.1. Company Overview

24.1.2. Key Executives

24.1.3. Operating Business Segments

24.1.4. Product Portfolio

24.1.5. Financial Performance (As per availability)

24.1.6 Key News

25.1 Pregna International Limited

25.1.1. Company Overview

25.1.2. Key Executives

25.1.3. Operating Business Segments

25.1.4. Product Portfolio

25.1.5. Financial Performance (As per availability)

25.1.6 Key News

26.1 Prosan International B.V.

26.1.1. Company Overview

26.1.2. Key Executives

26.1.3. Operating Business Segments

26.1.4. Product Portfolio

26.1.5. Financial Performance (As per availability)

26.1.6 Key News

27.1 SMB Corporation of India

27.1.1. Company Overview

27.1.2. Key Executives

27.1.3. Operating Business Segments

27.1.4. Product Portfolio

27.1.5. Financial Performance (As per availability)

27.1.6 Key News

28.1 Melbea Innovations

28.1.1. Company Overview

28.1.2. Key Executives

28.1.3. Operating Business Segments

28.1.4. Product Portfolio

28.1.5. Financial Performance (As per availability)

28.1.6 Key News

29.1 Ocon Medical Ltd.

29.1.1. Company Overview

29.1.2. Key Executives

29.1.3. Operating Business Segments

29.1.4. Product Portfolio

29.1.5. Financial Performance (As per availability)

29.1.6 Key News

30.1 Viatris Inc.

30.1.1. Company Overview

30.1.2. Key Executives

30.1.3. Operating Business Segments

30.1.4. Product Portfolio

30.1.5. Financial Performance (As per availability)

30.1.6 Key News

31.1 Agile Therapeutics, Inc.

31.1.1. Company Overview

31.1.2. Key Executives

31.1.3. Operating Business Segments

31.1.4. Product Portfolio

31.1.5. Financial Performance (As per availability)

31.1.6 Key News

32.1 Luye Pharma Group

32.1.1. Company Overview

32.1.2. Key Executives

32.1.3. Operating Business Segments

32.1.4. Product Portfolio

32.1.5. Financial Performance (As per availability)

32.1.6 Key News

33.1 Johnson & Johnson

33.1.1. Company Overview

33.1.2. Key Executives

33.1.3. Operating Business Segments

33.1.4. Product Portfolio

33.1.5. Financial Performance (As per availability)

33.1.6 Key News

34.1 Merck & Co., Inc.

34.1.1. Company Overview

34.1.2. Key Executives

34.1.3. Operating Business Segments

34.1.4. Product Portfolio

34.1.5. Financial Performance (As per availability)

34.1.6 Key News

35.1 Novo Nordisk

35.1.1. Company Overview

35.1.2. Key Executives

35.1.3. Operating Business Segments

35.1.4. Product Portfolio

35.1.5. Financial Performance (As per availability)

35.1.6 Key News

36.1 Pfizer, Inc.

36.1.1. Company Overview

36.1.2. Key Executives

36.1.3. Operating Business Segments

36.1.4. Product Portfolio

36.1.5. Financial Performance (As per availability)

36.1.6 Key News

37.1 Prasco Laboratories

37.1.1. Company Overview

37.1.2. Key Executives

37.1.3. Operating Business Segments

37.1.4. Product Portfolio

37.1.5. Financial Performance (As per availability)

37.1.6 Key News

38.1 The Cigna Group

38.1.1. Company Overview

38.1.2. Key Executives

38.1.3. Operating Business Segments

38.1.4. Product Portfolio

38.1.5. Financial Performance (As per availability)

38.1.6 Key News

39.1 Teva Pharmaceuticals, Inc.

39.1.1. Company Overview

39.1.2. Key Executives

39.1.3. Operating Business Segments

39.1.4. Product Portfolio

39.1.5. Financial Performance (As per availability)

39.1.6 Key News

40.1 Tree of Life Pharma Ltd.

40.1.1. Company Overview

40.1.2. Key Executives

40.1.3. Operating Business Segments

40.1.4. Product Portfolio

40.1.5. Financial Performance (As per availability)

40.1.6 Key News

41.1 The Good Glamm Group

41.1.1. Company Overview

41.1.2. Key Executives

41.1.3. Operating Business Segments

41.1.4. Product Portfolio

41.1.5. Financial Performance (As per availability)

41.1.6 Key News

42.1 BRANDMOVER GmbH

42.1.1. Company Overview

42.1.2. Key Executives

42.1.3. Operating Business Segments

42.1.4. Product Portfolio

42.1.5. Financial Performance (As per availability)

42.1.6 Key News

Global Contraceptive Devices Market Segmentation

Contraceptive Devices by Types: Market Size & Forecast 2023-2030

• Condoms
• IUDs
• Injectables
• Patches
• Vaginal Rings
• Diaphragms
• Cervical Caps
• Sponges
• Others

Contraceptive Devices by Distribution Channels: Market Size & Forecast 2023-2030

• Supermarkets, Hypermarkets, and Convenience Stores
• Retail Pharmacies, Hospital Pharmacies and Drug Stores
• Online Stores
• Others

Contraceptive Devices by Geography: Market Size & Forecast 2023-2030

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Major Players:

• Church & Dwight Co., Inc. (U.S.)
• Fuji Latex Co., Ltd. (Japan)
• Reckitt Benckiser Group (U.K.)
• Karex Berhad (Malaysia)
• Lelo (Sweden)
• LifeStyles Healthcare Pte Ltd. (Belgium)
• Veru, Inc. (U.S.)
• Mayer Laboratories, Inc. (U.S.)
• Okamoto Industries, Inc. (Japan)
• Cupid Limited (India)
• Caution Wear Corp. (U.S.)
• ONE Condoms (U.S.)
• Abbvie Inc. (U.S.)
• Bayer AG (Germany)
• CooperSurgical Inc. (U.S.)
• EUROGINE, S.L. (Spain)
• Mona Lisa N.V. (Belgium)
• Pregna International Limited (India)
• Prosan International B.V. (The Netherlands)
• SMB Corporation of India (India)
• Melbea Innovations (Hungary)
• Ocon Medical Ltd. (Israel),
• Viatris Inc. (U.S.)
• Agile Therapeutics, Inc. (U.S.)
• Luye Pharma Group (China)
• Johnson & Johnson (U.S.)
• Merck & Co., Inc. (U.S.)
• Novo Nordisk (Denmark)
• Pfizer, Inc. (U.S.)
• Prasco Laboratories (U.S.)
• The Cigna Group (U.S.)
• Teva Pharmaceuticals, Inc. (Israel)
• Tree of Life Pharma Ltd. (Israel)
• The Good Glamm Group (India)
• BRANDMOVER GmbH (Switzerland)